348 related articles for article (PubMed ID: 18423725)
1. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer.
Davis JW; Nakanishi H; Kumar VS; Bhadkamkar VA; McCormack R; Fritsche HA; Handy B; Gornet T; Babaian RJ
J Urol; 2008 Jun; 179(6):2187-91; discussion 2191. PubMed ID: 18423725
[TBL] [Abstract][Full Text] [Related]
2. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
3. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Kundu SD; Roehl KA; Yu X; Antenor JA; Suarez BK; Catalona WJ
J Urol; 2007 Feb; 177(2):505-9. PubMed ID: 17222621
[TBL] [Abstract][Full Text] [Related]
5. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy.
de Cremoux P; Ravery V; Podgorniak MP; Chevillard S; Toublanc M; Thiounn N; Tatoud R; Delmas V; Calvo T; Boccon-Gibod L
Eur Urol; 1997; 32(1):69-74. PubMed ID: 9266235
[TBL] [Abstract][Full Text] [Related]
6. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
Weckermann D; Dorn R; Trefz M; Wagner T; Wawroschek F; Harzmann R
J Urol; 2007 Mar; 177(3):916-20. PubMed ID: 17296375
[TBL] [Abstract][Full Text] [Related]
7. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
[TBL] [Abstract][Full Text] [Related]
8. The relationship between serum prostate specific antigen level and tumor volume persists in the current era.
Ochiai A; Troncoso P; Babaian RJ
J Urol; 2007 Mar; 177(3):903-6. PubMed ID: 17296372
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2009 Mar; 181(3):1091-7. PubMed ID: 19150091
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
11. Pathological features after radical prostatectomy in potential candidates for active monitoring.
Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ
J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer volume at biopsy predicts clinically significant upgrading.
Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
[TBL] [Abstract][Full Text] [Related]
13. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
Nakanishi H; Groskopf J; Fritsche HA; Bhadkamkar V; Blase A; Kumar SV; Davis JW; Troncoso P; Rittenhouse H; Babaian RJ
J Urol; 2008 May; 179(5):1804-9; discussion 1809-10. PubMed ID: 18353398
[TBL] [Abstract][Full Text] [Related]
14. Analysis of peripheral blood for prostate cells after autologous transfusion given during radical prostatectomy.
Stoffel JT; Topjian L; Libertino JA
BJU Int; 2005 Aug; 96(3):313-5. PubMed ID: 16042720
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cancers detected at only a sextant or alternative location.
Ochiai A; Troncoso P; Babaian RJ
BJU Int; 2008 Apr; 101(7):837-40. PubMed ID: 18070187
[TBL] [Abstract][Full Text] [Related]
17. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
18. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
19. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
[TBL] [Abstract][Full Text] [Related]
20. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]